Integrated Filing — IndAS



General information about company

Scrip Code 540701
NSE Symbol DCAL
MSEI Symbol NA
ISIN INE385W01011
Name of company Dishman Carbogen Amcis Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 19-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 14-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Contract Development and Manufacturing Organisation (CDMO), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, disinfectants etc.
Start date and time of board meeting 19-05-2026   14:00:00
End date and time of board meeting 19-05-2026   21:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. No
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 03-02-2026
Indicate Company website link for updated RPT policy of the Company https://imdcal.com/images/files/Investor-Relations/Policies%20of%20Dishman%20Carbogen%20Amcis%20Limited/Policy%20on%20materiality%20of%20Related%20Party%20Transactions%20and%20on%20dealing%20with%20Related%20Party%20Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable for the Quarter



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 6,872.00 23,156.00
Other income 2,883.00 8,452.00
Total income 9,755.00 31,608.00
2 Expenses
(a) Cost of materials consumed 1,335.00 5,567.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 353.00 (1,636.00)
(d) Employee benefit expense 2,118.00 8,663.00
(e) Finance costs 2,214.00 8,652.00
(f) Depreciation, depletion and amortisation expense 1,515.00 6,257.00
(f) Other Expenses
1 Other Expenditure 2,968.00 10,030.00
Total other expenses 2,968.00 10,030.00
Total expenses 10,503.00 37,533.00
3 Total profit before exceptional items and tax (748.00) (5,925.00)
4 Exceptional items 0.00 0.00
5 Total profit before tax (748.00) (5,925.00)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax (314.00) (2,085.00)
9 Total tax expenses (314.00) (2,085.00)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (434.00) (3,840.00)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (434.00) (3,840.00)
17 Other comprehensive income net of taxes (5,488.00) (10,986.00)
18 Total Comprehensive Income for the period (5,922.00) (14,826.00)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 3,136.00 3,136.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 3,85,087.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.28 -2.45
Diluted earnings (loss) per share from continuing operations -0.28 -2.45
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.28 -2.45
Diluted earnings (loss) per share from continuing and discontinued operations -0.28 -2.45
24 Debt equity ratio 0.1600 0.1600
25 Debt service coverage ratio 0.0600 0.0600
26 Interest service coverage ratio 0.700 0.700
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1. The Financial results (standalone and consolidated) have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 19th May, 2026. 2. These financial results (standalone and consolidated) have been prepared in compliance with Ind AS, as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable. 3. Statutory Auditors have carried out an audit of standalone as well as consolidated financial results of the Company for the year ended 31st March, 2026 and issued unmodified report thereon. 4. The figures for quarter ended 31st March, 2026 and for corresponding quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year to date figures up to the third quarter of the financial year. 5. The excess amount of consideration payable over net assets acquired had been recorded as goodwill amounting to INR 1,326.86 crores in the amalgamation held between Dishman Pharmaceuticals and Chemical Limited and Dishman Care Limited into Dishman Carbogen Amcis Limited accounted in the year 2016-17 as per the Scheme of Amalgamation approved by the Hon’ble High Court, Gujarat, which is different from Ind AS 103 “Business Combinations”. The same was represented by underlying intangible assets acquired on amalgamation and was being amortized over the period of 15 years from the Appointed Date i.e. 1st January, 2015. The value of the Goodwill had already been reduced by Rs. 641.28 crores by March 31, 2022, the Board reassessed the life of the Goodwill looking at the expected growth and benefits available to the Company. Taking a conservative view, considering the possible impact of COVID and the delay in clearance of EDQM observations for the Bavla site, the Board revised the useful life of goodwill to 15 years starting from 1st April 2022 instead of the remainder useful life of 7 years, with a next time frame to further re-assess the same after COVID and major regulatory clearance. After successfully completing all major regulatory audit in last six to twelve months and the impact of COVID having phased out, the Board now expects the performance of the India business to improve and the current value of Goodwill as on 1st April, 2024 of INR 594.17 Crores as reflecting a fair value of the intangible assets for a sustainably long period. The robust outlook in the CDMO sector also supports the company’s path for growth. Considering all above factors, Board has decided to keep the current goodwill value of INR 594.17 Crores till perpetuity i.e. 99 years considering life with effect from 1st January, 2015. This change in estimate of life will be applicable prospectively over the remaining useful life starting from 1st April, 2024. The goodwill will tested for impairment at the end of every financial year. Had the goodwill not been amortized as required under Ind AS 103, the Depreciation and Amortization expense for the quarter ended 31st March, 2026, 31st December, 2025, 31st March, 2025, for the year ended 31st March, 2026 and for the year ended 31st March, 2025 would have been lower by INR 1.63 crores, INR 1.66 crores, INR 1.63 crores, INR 6.60 crores and INR 6.60 crores, respectively, and the Profit Before Tax for the corresponding periods would have been higher by an equivalent amount. 6. The financial results are available for perusal on the Company’s website: www.imdcal.com as well as on the Stock Exchange’s websites i.e. on www.bseindia.com and www.nseindia.com. 7. Group is required to disclose segment information based on the ‘management approach’ as defined in Ind AS 108- Operating Segments, which is how the Chief Operating Decision Maker (CODM) evaluates the Group’s performance and allocates resources based on the analysis of the various performance indicators. CODM reviews the results of the Group engaged in the business of Contract Development and Manufacturing Organisation (CDMO), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, disinfectants etc. Accordingly, Group as a whole is a single segment. The information as required under Ind AS 108 is available directly from the financial statements, hence no separate disclosure has been made. 8. Consolidated financial results comprise the results of the parent Company, Dishman Carbogen Amcis Limited and its subsidiaries (together referred as “the Group”) viz. Dishman CARBOGEN AMCIS (Europe) Ltd., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd, CARBOGEN AMCIS Holdings AG., Switzerland; CARBOGEN AMCIS (Shanghai) Co. Ltd.,; CARBOGEN AMCIS BV, Carbogen Amcis Ltd., U.K., CARBOGEN AMCIS AG (“CGAM AG”), Switzerland, CARBOGEN AMCIS SAS, Dishman Carbogen Amcis (Japan) Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd.,; Dishman Biotech Ltd.; CARBOGEN AMICS Innovations AG.; DISHMAN CARBOGEN AMCIS AG.; CARBOGEN AMCIS Real Estate, Dishman Medicare Limited (formerly known as Visible Investment Limited) and Dishman Carbogen AMCIS Technology AG. 9. During the quarter and year ended 31st March, 2026, one of the subsidiaries discarded some of their inventories, which was not expected to be usable for projects that the company estimated to undertake in near to mid-term. The loss on account of these impairments were Rs. 1.15 Crores and Rs. 3.80 Crores respectively for the quarter and year. 10. The Company’s one of the wholly owned subsidiaries, Carbogen Amcis Specialities AG got merged with another wholly owned subsidiary, Carbogen Amcis Innovation AG, on 9th October, 2025 with retrospective effect from 1st April, 2025. 11. Pursuant to the notification/implementation of the Labour Codes, namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the “Labour Codes”), the Company has assessed the potential impact of the changes on employee benefit obligations, including gratuity and leave-related benefits, based on the information currently available and applicable guidance. Based on the assessment carried out by the management, the impact of the Labour Codes on the Company's financial statements is not material. Accordingly, the impact, if any, has been considered and recognised as part of employee benefits expense in the financial results for the year ended March 31, 2026. The Company continues to monitor further developments, clarifications and the finalisation of related rules/implementation aspects and will evaluate and account for any consequential impact, if required, in future periods. 12. (a) the Company had issued senior, secured, rated, listed, taxable, redeemable, transferable, nonconvertible debentures of INR 49.99 crores (Indian Rupees Forty Nine Crore and Ninety Nine Lakh only) having ISIN INE385W07034 and has maintained 100% security cover of the principal and interest amount as on 31st March, 2026 by creating first ranking exclusive charge on identified land parcel being Freehold Non Agricultural land belonging to the Dishman Infrastructure Limited. Semiannually interest payment due on 15th January, 2026 has been paid during 12th January, 2026 to 13th January, 2026 and there was no principal payment falling due during the quarter ended 31st March, 2026. However, as per the terms of Debentures, some of the Debenture holders have exercised PUT Option, and the Company has made payment to the said Debenture holders towards such PUT Option. Accordingly, as on 31st March, 2026 principal amount of Debentures outstanding is INR 35.38 Crores. (b) the Company had issued Rated, Listed, Senior, Secured, Redeemable, Taxable Non-Convertible Debentures of INR 50.00 crores (Indian Rupees Fifty Crores only) having ISIN INE385W07042 and has maintained 100% security cover of the principal and interest amount as on 31st March, 2026 by creating first ranking exclusive charge on identified land parcel being Freehold Non Agricultural land belonging to the Dishman Infrastructure Limited. Quarterly interest payment due on 26th March, 2026 has been paid during 23rd March, 2026 to 26th March, 2025 and there was no principal payment falling due during the quarter ended 31st March, 2026. 13. As at 31st March, 2026, the Company was in compliance with all stipulated financial covenants at a consolidated group level. However, there was a deviation to one of the India standalone financial covenants in relation to two borrowing arrangements. The Company has three series of listed non-convertible debentures aggregating to Rs. 133.36 Crores outstanding as at 31st March, 2026. In respect of two series of debentures, namely Debenture Series 2024 and Debenture Series 2025 aggregating to Rs. 84.44 Crores, the Company did not satisfy one of the stipulated financial covenants at the India standalone financial statement level as at the reporting date. However, the Company was in full compliance with the financial covenants at the consolidated financial statement level. The Company had requested waiver from the respective debenture holders before 31st March, 2026 for permitting the deviation from the one standalone financial covenant and certain debenture holders had already provided the waiver in the above respect by March 31, 2026. The balance waivers from other debenture holders are awaited as on the date of approval of these financial results. Since these debentures are contractually due for repayment during FY 2026-27, there is no change in the classification of these debts as current liabilities as at 31st March 2026. In respect of Debenture Series 2026 aggregating to Rs. 48.92 Crores, the Company had obtained waiver for covenant non-compliance from the respective debenture holders prior to 31st March, 2026. Further, in respect of term loan facility aggregating to Rs. 63.67 Crores, the Company obtained waiver for covenant non-compliance from the respective lenders subsequent to the reporting date but prior to approval of these financial results. The management believes that the aforesaid deviation from standalone financial covenant is procedural in nature and does not impact the Company’s ability to meet its repayment obligations. 14. The Board of Directors in its meeting held on 27th December, 2025, have approved the issuance up to 5,000 (Five Thousand) Senior, Secured, Rated, Listed, Taxable, Redeemable, Transferable, Non- Convertible Debentures denominated in Indian Rupees (INR), having a face value of INR 1,00,000 (Indian Rupees One Lakh) each and an aggregate nominal value of INR 50,00,00,000 (Indian Rupees Fifty Crores only) on a private placement basis (“Debentures”) and on 20th January, 2026 the Company has allotted 5,000 (five thousand) Debentures amounting to INR 50,00,00,000 (Indian Rupees Fifty Crores) and has received Listing and trading approval from BSE Limited vide its notice dated 21st January, 2026. There is no deviation in use of proceeds from the objects stated in the Disclosure Document. The Secured Non-convertible Debentures of the Company aggregating INR 50.00 crores (Indian Rupees Fifty Crores only) as on 31st March, 2026 are secured by creating charge on (i) identified properties of the Company, (ii) identified properties of the Promoter of the Company viz. Mr. Arpit J. Vyas and (iii) identified land parcel being Freehold Non Agricultural land belonging to the Dishman Infrastructure Limited. The asset cover in respect of the Secured Debentures of the Company as on 31st March, 2026 is 100% of the principal and interest amount of the said Secured Non-convertible Debentures. Statement of utilization of issue proceeds: (INR in Crores) Name of the Issuer - Dishman Carbogen Amcis Ltd ISIN - INE385W07059 Mode of Fund Raising (Public issues/ Private placement) - Private Placement Type of instrument - Secured Nonconvertible Debentures Date of raising funds - 20/01/26 Amount Raised - 50.00 Funds utilized - 50.00 Any deviation (Yes/ No) - No If 8 is Yes, then specify the purpose of for which the funds were utilized - NA Remarks, if any - None Statement of deviation/ variation in use of Issue proceeds: Particulars - Remarks Name of listed entity - Dishman Carbogen Amcis Ltd Mode of fund raising - Private Placement Type of instrument - Secured Non-convertible Debentures Date of raising funds - 20/01/2026 Amount raised - INR 50.00 Crores Report filed for quarter ended - 31/03/2026 Is there a deviation/ variation in use of funds raised? - No Whether any approval is required to vary the objects of the issue stated in the prospectus/ offer document? - No If yes, details of the approval so required? - NA Date of approval - NA Explanation for the deviation/ variation - NA Comments of the audit committee after review - This statement as on March 31, 2026, was placed before the Audit Committee at its meeting held on May 19, 2026. The Committee noted the same. Comments of the auditors, if any - NA Objects for which funds have been raised and where there has been a deviation/ variation, in the following table: Original object - The proceeds of the issue has been utilized for the following purposes: Capital Expenditure requirements including Maintenance expenditure and reimbursement. Working Capital requirements. There is no deviation / variation, in the utilization. Modified object, if any - NA Original allocation - NA Modified allocation, if any - NA Funds utilised - NA Amount of deviation/ variation for the quarter according to applicable object (in Rs. crore and in %) - NA Remarks, if any - NA Deviation could mean: a. Deviation in the objects or purposes for which the funds have been raised. b. Deviation in the amount of funds actually utilized as against what was originally disclosed. 15. The company has decided to exercise the option available under Section 200 of the Income Tax Act, 2025, and accordingly, the provisions of the said section shall be applicable to the company with effect from FY 2026–27 onwards. Hence, effective tax rate has changed. 16. The previous quarter / year figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable. 17. The Company is not a Large Corporate as per the applicability criteria given under the Chapter XII of SEBI Operational circular no. SEBI/HO/DDHS/P/CIR/ 2021/613 dated August 10, 2021, read with SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023. On behalf of the Board of Directors Arpit Vyas Global Managing Director DIN - 01540057 Place: Vitznau Date: 19th May, 2026



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 78,198.00
Capital work-in-progress 2,268.00
Investment property
Goodwill 58,096.00
Other intangible assets 193.00
Intangible assets under development 29.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 2,82,824.00
Trade receivables, non-current 0.00
Loans, non-current 821.00
Other non-current financial assets
1 Other Non Current Financial Assets 1,097.00
2 Non-current tax assets 11,651.00
Total of other non-current financial assets 12,748.00
Total non-current financial assets 2,96,393.00
Deferred tax assets (net) 2,860.00
Other non-current assets
1 Other non-current assets 4,886.00
2 Right of use assets 711.00
Total of other non-current assets 5,597.00
Total non-current assets 4,43,634.00
2 Current assets
Inventories 15,512.00
Current financial asset
Current investments 1,600.00
Trade receivables, current 17,062.00
Cash and cash equivalents 1,593.00
Bank balance other than cash and cash equivalents 2,209.00
Loans, current 24,443.00
Other current financial assets
Total of other current financial assets 3,920.00
Total current financial assets 50,827.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 2,631.00
Total of other current assets 2,631.00
Total current assets 68,970.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 5,12,604.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 3,136.00
Other equity 3,85,087.00
Total equity attributable to owners of parent 3,88,223.00
Non controlling interest
Total equity 3,88,223.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 12,386.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 6,074.00
Total of other non-current financial liabilities 6,074.00
Total non-current financial liabilities 18,460.00
Provisions, non-current 681.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current
Other non-current liabilities
1 Other non-current liabilities 18,350.00
Total of other non-current liabilities 18,350.00
Total non-current liabilities 37,491.00
Current liabilities
Current financial liabilities
Borrowings, current 50,676.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 697.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 6,832.00
Total Trade payable 7,529.00
Other current financial liabilities
1 Other current financial liabilities 15,695.00
2 Lease liabilities 355.00
Total of other current financial liabilities 16,050.00
Total current financial liabilities 74,255.00
Other current liabilities 12,387.00
1 Other current liabilities 12,387.00
Total of other current liabilities 12,387.00
Provisions, current 248.00
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 86,890.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 1,24,381.00
Total equity and liabilites 5,12,604.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re measurement gains/ (Losses) on defined benefit plans (57.00) (1.00)
2 Changes in fair value of FVTOCI equity instruments 338.00 339.00
Total Amount of items that will not be reclassified to profit and loss 281.00 338.00
2 Income tax relating to items that will not be reclassified to profit or loss 696.00 716.00
3 Amount of items that will be reclassified to profit and loss
1 Foreign exchange fluctuation in respect of cash flow hedge (4,983.00) (13,491.00)
Total Amount of items that will be reclassified to profit and loss (4,983.00) (13,491.00)
4 Income tax relating to items that will be reclassified to profit or loss 90.00 (2,883.00)
5 Total Other comprehensive income (5,488.00) (10,986.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (5,925.00)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories (2,087.00)
Adjustments for decrease (increase) in trade receivables, current 1,370.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (968.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 5,560.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 6,257.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (5,040.00)
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (14.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 5,078.00
Net cash flows from (used in) operations (847.00)
Dividends received (777.00)
Interest paid (8,652.00)
Interest received (2,165.00)
Income taxes paid (refund) 252.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 4,611.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 15.00
Purchase of property, plant and equipment 2,699.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties (3,414.00)
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 777.00
Interest received 366.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 295.00
Net cash flows from (used in) investing activities 2,168.00
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 15,346.00
Repayments of borrowings 20,140.00
Payments of lease liabilities (1,400.00)
Dividends paid 0.00
Interest paid 8,565.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (11,959.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (5,180.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (5,180.00)
Cash and cash equivalents cash flow statement at beginning of period 6,773.00
Cash and cash equivalents cash flow statement at end of period 1,593.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 T R CHADHA & CO. LLP Yes 30-09-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Dishman Carbogen Amcis Limited Azafran Innovacion Ltd Entity in which KMP can exercise significant influence Sale of goods or services 100.00 None 0.00 19.00 21.00
2 Dishman Carbogen Amcis Limited Azafran Innovacion Ltd Entity in which KMP can exercise significant influence Any other transaction Rendering of Services 4.00 None 2.00 17.00 19.00
3 Dishman Carbogen Amcis Limited Dishman Infrastructure Ltd Entity in which KMP can exercise significant influence Any other transaction Rendering of Services 125.00 None 1.00 4.00 5.00
4 Dishman Carbogen Amcis Limited Dishman Infrastructure Ltd Entity in which KMP can exercise significant influence Loan 3,000.00 None (1,541.00) 2,750.00 0.00 Textual Information(1)
5 Dishman Carbogen Amcis Limited Dishman Infrastructure Ltd Entity in which KMP can exercise significant influence Interest paid 400.00 None 51.00 0.00 42.00
6 Carbogen Amcis BV, Netherlands Dishman Infrastructure Ltd Entity in which KMP can exercise significant influence Any other transaction Interest Income on CCD Not Applicable 0.00 222.00 233.00
7 Dishman Biotech Limited Dishman Infrastructure Ltd Entity in which KMP can exercise significant influence Any other transaction Lease Advances Given 100.00 None (11.00) 345.00 334.00 Advance 0 0 Unsecured Lease advance given for land availed on lease
8 Dishman Carbogen Amcis Limited Mrs. Deohooti J.Vyas KMP - Executive Director Remuneration 240.00 None 60.00 0.00 0.00
9 Dishman Carbogen Amcis Limited Mrs. Deohooti J.Vyas KMP - Executive Director Any other transaction Receiving of Services 40.00 None 23.00 0.00 0.00
10 Carbogen Amcis Innovations AG Ms. Pankti H. Dalal Relative of KMP Remuneration 255.00 None 137.00 0.00 0.00
11 Dishman Carbogen Amcis Limited Adimans Technologies LLP Holding Entity Any other transaction Rendering of Services 1.00 None 1.00 3.00 4.00
12 Dishman Carbogen Amcis Limited Adimans Technologies LLP Holding Entity Any other transaction Receiving of Services 100.00 None 3.00 9.00 12.00
13 Dishman Carbogen Amcis Limited B.R.Laboratories Limited Entity in which KMP can exercise significant influence Any other transaction Rendering of Services 1.00 None 1.00 3.00 4.00
14 Dishman Carbogen Amcis Limited Azafran Ventures Private Limited Entity in which KMP can exercise significant influence Any other transaction Rendering of Services 1.00 None 1.00 3.00 4.00
15 Dishman Carbogen Amcis Limited Leon Hospitality Private Limited Entity in which KMP can exercise significant influence Any other transaction Rendering of Services 1.00 None 1.00 3.00 4.00
16 Dishman Carbogen Amcis Limited Aham Brahamasmi Entertainment Private Limited Entity in which KMP can exercise significant influence Any other transaction Rendering of Services 1.00 None 1.00 3.00 4.00
17 Dishman Carbogen Amcis Limited Discus IT Private Limited Entity in which KMP can exercise significant influence Any other transaction Receiving of Services 350.00 None 165.00 0.00 26.00
18 Dishman Carbogen Amcis Limited Discus Business Services LLP Entity in which KMP can exercise significant influence Any other transaction Receiving of Services 50.00 None 7.00 4.00 12.00
19 Dishman Carbogen Amcis Limited Harshil R. Dalal HUF Key Management Personnel is Karta Any other transaction Receiving of Services 18.00 None 6.00 8.00 1.00
20 Dishman Carbogen Amcis Limited Harshil R. Dalal HUF Key Management Personnel is Karta Any other transaction Advance received 325.00 None 7.00 212.00 243.00
21 Dishman Carbogen Amcis Limited Mr. Arpit Vyas KMP - Executive Director Any other transaction Receiving of Services 19.00 None 7.00 17.00 25.00
22 Carbogen Amcis AG Mr. Arpit Vyas KMP - Executive Director Remuneration 1,050.00 None 595.00 0.00 0.00
23 Carbogen Amcis AG, Switzerland Mr. Arpit Vyas KMP - Executive Director Any other transaction Loan given/(repaid) Not Applicable 17.00 37.00 54.00 Loan 2.8500 On demand Unsecured For leasing of movable property and General Purpose
24 Dishman Biotech Limited Mr. Arpit Vyas KMP - Executive Director Any other transaction Loan taken/(repaid) 2,000.00 None 1,616.00 884.00 2,500.00
25 Dishman Carbogen Amcis (Europe) Limited Mr. Arpit Vyas KMP - Executive Director Any other transaction Loan given/(repaid) No Applicable 140.00 8.00 147.00 Loan 2.500 On demand Unsecured General Purpose
26 Dishman Carbogen Amcis Technology AG Mr. Arpit Vyas KMP - Executive Director Any other transaction Loan taken/(repaid) 1,000.00 None (139.00) 139.00 0.00
27 Dishman Carbogen Amcis Limited Mr. Arpit Vyas KMP - Executive Director Any other transaction Loan taken/(repaid) 1,000.00 None 42.00 195.00 237.00
28 Dishman Biotech Limited Mr. Arpit Vyas KMP - Executive Director Interest paid 100.00 None 28.00 15.00 0.00
29 Carbogen Amcis Holding AG Mrs. Saloni Vyas KMP - Executive Director Remuneration 275.00 None 149.00 0.00 0.00
30 Dishman Carbogen Amcis Limited Ms Aditi J. Vyas Relative of KMP Any other transaction Receiving of Services 16.00 None 14.00 32.00 14.00
31 Dishman Carbogen Amcis Limited Ms Aditi J. Vyas Relative of KMP Remuneration 60.00 None 32.00 0.00 0.00
32 Dishman Carbogen Amcis Limited Creciente Direct Private Limited Entity in which KMP can exercise significant influence Any other transaction Receiving of Services 250.00 None 0.00 292.00 292.00
33 Dishman Carbogen Amcis Limited J.R Vyas HUF Entity in which KMP can exercise significant influence Any other transaction Receiving of Services 16.00 None 12.00 (4.00) 12.00
34 Dishman Carbogen Amcis Limited Ms Mansi J. Vyas Relative of KMP Remuneration 60.00 None 32.00 0.00 0.00
35 Dishman Carbogen Amcis Limited Nikunj Desai Relative of KMP Any other transaction Advances received 285.00 None 0.00 52.00 52.00
36 Carbogen Amcis AG, Switzerland Zenon Therapeutics AG Entity in which KMP can exercise significant influence Any other transaction Rendering of Services Not Applicable 149.00 580.00 0.00
37 Dishman Carbogen Amcis Technology AG Aamanya AG Entity in which KMP can exercise significant influence Any other transaction Advance Repaid 100.00 None (95.00) 95.00 0.00 Advance 0 0 Unsecured General Business Purpose
38 Carbogen Amcis Innovations AG Aamanya AG Entity in which KMP can exercise significant influence Any other transaction Receiving of Services 12,200.00 None 3,696.00 3,953.00 7,649.00
39 Dishman Carbogen Amcis (Singapore) Pte. Ltd Aamanya AG Entity in which KMP can exercise significant influence Any other transaction Loan taken 2,000.00 None 1,797.00 0.00 1,797.00
40 Dishman Cabrogen Amcis Technologies AG Aamanya AG Entity in which KMP can exercise significant influence Any other transaction Loan taken 500.00 None 359.00 0.00 359.00
41 Dishman Cabrogen Amcis AG Aamanya AG Entity in which KMP can exercise significant influence Any other transaction Loan taken/(repaid) 100.00 None 0.00 0.00 30.00
Total value of transaction during the reporting period 7,366.00



Text Block

Textual Information(1) Loan Repaid